Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058005 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT01058005 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 84 participants.
The verdict
NCT01058005, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer acetate.
Interventions
- DRUG glatiramer acetate
- DRUG BG00002 (natalizumab)
- DRUG interferon beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058005
The ClinicalTrials.gov registry entry for NCT01058005 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which glatiramer acetate is the first listed.
NCT01058005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01058005 about?
NCT01058005 is a clinical study titled "Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis". This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer ...
What is the current status of trial NCT01058005?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2010-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01058005?
The interventions under investigation include: glatiramer acetate (DRUG), BG00002 (natalizumab) (DRUG), interferon beta-1a (DRUG).
Who is sponsoring clinical trial NCT01058005?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.